Novo Nordisk Class Action Investigation: Potential Claims Against Pharmaceutical Company

Investors who suffered losses exceeding $100,000 in Novo Nordisk A/S between May 7, 2025, and July 28, 2025, may be eligible to discuss their options with lead securities litigation partner James (Josh) Wilson of Faruqi & Faruqi, LLP. The firm is investigating potential claims against Novo Nordisk, alleging that the company and its executives violated federal securities laws by making false and/or misleading statements. The class action lawsuit claims that Novo Nordisk's growth potential was understated, and its capability to penetrate the GLP-1 market was overstated. The company's stock price fell dramatically after it announced a lowered sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025.

Key Takeaways:

• The class action lawsuit alleges that Novo Nordisk and its executives made false and/or misleading statements about the company's growth potential and its capability to penetrate the GLP-1 market.
• The lawsuit claims that the company understated its growth potential and overstated its ability to capitalize on the market.
• Novo Nordisk's stock price fell by 21.83% in a single day after the company announced a lowered sales and profit outlook.
• Investors who suffered losses exceeding $100,000 may be eligible to discuss their options with lead securities litigation partner James (Josh) Wilson.
• The firm is investigating potential claims against Novo Nordisk and encourages anyone with information regarding the company's conduct to contact them.
• The deadline to seek the role of lead plaintiff in the federal securities class action is September 30, 2025.

Statistics:

• $69.00: the closing market price of Novo's common stock on July 28, 2025
• $53.94: the price of Novo's stock on July 29, 2025, after the company announced its lowered sales and profit outlook
• 21.83%: the decline in Novo's stock price in a single day
• 100,000: the minimum amount of losses required to be eligible to discuss options with lead securities litigation partner James (Josh) Wilson
• September 30, 2025: the deadline to seek the role of lead plaintiff in the federal securities class action

Sources:

• Newsfile Corp.
• Faruqi & Faruqi, LLP
• Novo Nordisk A/S (NYSE: NVO)